Literature DB >> 14576537

The "intubating dose" of succinylcholine: the effect of decreasing doses on recovery time.

Aaron F Kopman1, Bledi Zhaku, Kane S Lai.   

Abstract

BACKGROUND: The usually cited "intubation dose" of succinylcholine is 1.0 mg/kg. In the majority of patients, this dose will produce apnea of sufficient duration that significant hemoglobin desaturation may occur before neuromuscular recovery takes place in those whose ventilation is not assisted. This study was undertaken to examine the extent to which reducing this dose would decrease the duration of action of succinylcholine.
METHODS: During stable desflurane/oxygen/opioid anesthesia and after adequate twitch stabilization, neuromuscular function was recorded with an acceleromyographic monitor. Supramaximal stimuli were delivered at 0.10 Hz. Patients received 0.40, 0.60, or 1.0 mg/kg succinylcholine, and twitch height was monitored for at least 20 min thereafter.
RESULTS: The onset times to maximal effect were 105 +/- 23 s, 81 +/- 19 s, and 71 +/- 22 s, respectively. The lowest dose (0.40 mg/kg) did not reliably produce 100% twitch depression. The times to 90% twitch recovery at the adductor pollicis in the three groups were 6.6 +/- 1.5 min, 7.6 +/- 1.6 min, and 9.3 +/- 1.2 min, respectively.
CONCLUSIONS: Reducing the dose of succinylcholine from 1.0 mg/kg to 0.60 mg/kg shortens the duration of effect at the adductor pollicis by more than 90 s. The authors believe that even this modest decrease in the duration of drug-induced paralysis is often worth pursuing.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14576537     DOI: 10.1097/00000542-200311000-00007

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  9 in total

Review 1.  [Sugammadex. New pharmacological concept for antagonizing rocuronium and vecuronium].

Authors:  H J Sparr; L H Booij; T Fuchs-Buder
Journal:  Anaesthesist       Date:  2009-01       Impact factor: 1.041

2.  [Modified rapid sequence induction for Caesarian sections : case series on the use of rocuronium and sugammadex].

Authors:  D Nauheimer; C Kollath; G Geldner
Journal:  Anaesthesist       Date:  2012-08       Impact factor: 1.041

3.  Comparison of intubation conditions and apnea time after anesthesia induction with propofol/remifentanil combined with or without small dose of succinylcholine.

Authors:  Jing Jiao; Shaoqiang Huang; Yingjie Chen; Hailian Liu; Yi Xie
Journal:  Int J Clin Exp Med       Date:  2014-02-15

4.  Quantitative Intraoperative Torsional Forced Duction Test.

Authors:  Jae Ho Jung; Jonathan M Holmes
Journal:  Ophthalmology       Date:  2015-06-27       Impact factor: 12.079

5.  Preoxygenation with 20º head-up tilt provides longer duration of non-hypoxic apnea than conventional preoxygenation in non-obese healthy adults.

Authors:  Venkateswaran Ramkumar; Goneppanavar Umesh; Frenny Ann Philip
Journal:  J Anesth       Date:  2011-02-04       Impact factor: 2.078

6.  Intraoperative Findings in Consecutive Exotropia with and without Adduction Deficit.

Authors:  Sarah R Hatt; David A Leske; Jae Ho Jung; Jonathan M Holmes
Journal:  Ophthalmology       Date:  2017-02-24       Impact factor: 12.079

7.  The optimal succinylcholine dose for intubating emergency patients: retrospective comparative study.

Authors:  Alaa Ezzat; Essam Fathi; Ahmad Zarour; Rajvir Singh; M Osama Abusaeda; M Magdy Hussien
Journal:  Libyan J Med       Date:  2011-07-14       Impact factor: 1.657

Review 8.  Optimal dose of succinylcholine for laryngeal mask airway insertion: systematic review, meta-analysis and metaregression of randomised control trials.

Authors:  Alan Hsi-Wen Liao; Yu-Cih Lin; Chyi-Huey Bai; Chien-Yu Chen
Journal:  BMJ Open       Date:  2017-08-04       Impact factor: 2.692

9.  The optimal dose of succinylcholine for rapid sequence induction: a systematic review and meta-analysis of randomized trials.

Authors:  Alessandro Putzu; Martin R Tramèr; Maxim Giffa; Christoph Czarnetzki
Journal:  BMC Anesthesiol       Date:  2020-03-02       Impact factor: 2.217

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.